MAP Stock Overview
Provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Microba Life Sciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.17 |
| 52 Week High | AU$0.23 |
| 52 Week Low | AU$0.14 |
| Beta | 2.7 |
| 11 Month Change | 4.69% |
| 3 Month Change | -1.47% |
| 1 Year Change | -22.09% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -52.14% |
Recent News & Updates
Shareholder Returns
| MAP | AU Healthcare | AU Market | |
|---|---|---|---|
| 7D | 11.7% | -4.2% | 0.4% |
| 1Y | -22.1% | -1.8% | 16.9% |
Return vs Industry: MAP underperformed the Australian Healthcare industry which returned -1.8% over the past year.
Return vs Market: MAP underperformed the Australian Market which returned 16.9% over the past year.
Price Volatility
| MAP volatility | |
|---|---|
| MAP Average Weekly Movement | 8.6% |
| Healthcare Industry Average Movement | 5.2% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.4% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: MAP has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: MAP's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | Luke Reid | microba.com |
Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates through two segments, Testing Services and Supplements, and Research and Development. The company also develops pathology, therapeutics, and diagnostics services based on the human gut microbiome.
Microba Life Sciences Limited Fundamentals Summary
| MAP fundamental statistics | |
|---|---|
| Market cap | AU$75.02m |
| Earnings (TTM) | -AU$19.94m |
| Revenue (TTM) | AU$12.09m |
6.2x
P/S Ratio-3.8x
P/E RatioIs MAP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MAP income statement (TTM) | |
|---|---|
| Revenue | AU$12.09m |
| Cost of Revenue | AU$6.18m |
| Gross Profit | AU$5.91m |
| Other Expenses | AU$25.84m |
| Earnings | -AU$19.94m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.045 |
| Gross Margin | 48.85% |
| Net Profit Margin | -164.92% |
| Debt/Equity Ratio | 1.0% |
How did MAP perform over the long term?
See historical performance and comparison